Inhibrx Biosciences, Inc.
Business
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel biologic therapeutic candidates using proprietary modular protein engineering platforms. The company's pipeline includes ozekibart (INBRX-109), a tetravalent DR5 agonist in Phase 2 trials for oncology indications including chondrosarcoma, Ewing sarcoma, and colorectal cancer, and INBRX-106, a hexavalent OX40 agonist in Phase 1/2 trials for solid tumors often in combination with pembrolizumab. Inhibrx operates globally and recently separated from its former parent company in May 2024, focusing on advancing its internal clinical programs through internal research and contracted manufacturing relationships.
Summary from 10-K filed 2026-03-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Total revenue | 1 | 200,000 | 2 | |
| Research and development | 113 | 204 | 192 | |
| General and administrative | 23 | 128 | 29 | |
| Total operating expenses | 136 | 332 | 221 | |
| Loss from operations | −135 | −331 | −219 | |
| Gain related to transaction with Acquirer | 0 | 2,000 | 0 | |
| Interest expense | −12 | −13 | −32 | |
| Interest income | 8 | 11 | 12 | |
| Other income (expense), net | −381,000 | 75,000 | −580,000 | |
| Total other income (expense) | −5 | 2,019 | −21 | |
| Income (loss) before provision for income taxes | −140 | 1,688 | — | |
| Provision for income taxes | 2,000 | 2,000 | 3,000 | |
| Net income (loss) | −140 | 1,688 | −241 | |
| Basic (in dollars per share) | −9.04 | 114.01 | −20.48 | |
| Diluted (in dollars per share) | −9.04 | 112.62 | −20.48 | |
| Basic (in shares) | 15 | 15 | 12 | |
| Diluted (in shares) | 15 | 15 | 12 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 124 | 153 | 278 | — | |
| Other receivables | 177,000 | 197,000 | — | — | |
| Prepaid expenses and other current assets | 8 | 7 | 17 | — | |
| Total current assets | 133 | 160 | 295 | — | |
| Property and equipment, net | 4 | 6 | 6 | — | |
| Operating right-of-use asset | 6 | 7 | 3 | — | |
| Other non-current assets | 4 | 7 | 3 | — | |
| Total assets | 146 | 181 | 308 | — | |
| Accounts payable | 6 | 9 | 11 | — | |
| Accrued expenses | 26 | 30 | 43 | — | |
| Current portion of operating lease liability | 2 | 2 | 2 | — | |
| Total current liabilities | 34 | 41 | 56 | — | |
| Long-term debt, including final payment fee | 101 | 0 | 207 | — | |
| Non-current portion of operating lease liability | 4 | 6 | 1 | — | |
| Total liabilities | 138 | 47 | 264 | — | |
| Commitments and contingencies (Note 10) | — | — | — | — | |
| Preferred stock, $0.0001 par value, 15,000,000 shares authorized and no shares outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | — | |
| Common stock, $0.0001 par value, 120,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 14,577,609 and 14,475,904 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 1,000 | 1,000 | 5,000 | — | |
| Additional paid-in-capital | 254 | 240 | 657 | — | |
| Accumulated deficit | −246 | −106 | −614 | — | |
| Total stockholders equity | 8 | 134 | 44 | 58 | |
| Total liabilities and stockholders equity | 146 | 181 | 308 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Depreciation and amortization | 2 | 2 | 1 | |
| Accretion of debt discount and non-cash interest expense | 2 | 2 | 5 | |
| Stock-based compensation expense | 11 | 59 | 25 | |
| Non-cash lease expense | 2 | 2 | 2 | |
| Non-cash gain on transaction with Acquirer | 0 | −1,999 | 0 | |
| Loss on disposal of property and equipment | 12,000 | 12,000 | 3,000 | |
| Accounts receivable | 200,000 | −185,000 | −535,000 | |
| Other receivables | 20,000 | 566,000 | — | |
| Receivables from related parties | 23,000 | −23,000 | 14,000 | |
| Prepaid expenses and other current assets | 1 | 3 | −10 | |
| Other non-current assets | 0 | −4 | 0 | |
| Accounts payable | −3 | 18 | 2 | |
| Accrued expenses | −4 | 36 | 26 | |
| Operating lease liability | −2 | −1 | −2 | |
| Net cash used in operating activities | −130 | −194 | −193 | |
| Purchase of property and equipment | −31,000 | −3 | −5 | |
| Proceeds from the sale of property and equipment | 3,000 | 0 | — | |
| Net cash used in investing activities | −28,000 | −3 | −5 | |
| Proceeds from the issuance of debt | 100 | 0 | — | |
| Payment of third-party fees associated with debt | −125,000 | 0 | — | |
| Proceeds from exercise of stock options | 2 | 72 | 2 | |
| Net cash provided by financing activities | 101 | 72 | 202 | |
| Net decrease in cash | −28 | −125 | 4 | |
| Cash paid for interest | 9 | 12 | 27 | |
| Cash paid for income taxes | 2,000 | 2,000 | 3,000 | |
| Remeasurement of operating lease liability and right-of-use asset in connection with 2024 Lease Agreement | 0 | 6 | 0 | |
| Fair value of warrants issued to lender in conjunction with 2025 Loan Agreement (as defined in Note 3) | 2 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Inhibrx Biosciences, Inc.'s CIK number?
Inhibrx Biosciences, Inc.'s SEC CIK number is 0002007919 (2007919). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Inhibrx Biosciences, Inc.'s SEC filings?
All of Inhibrx Biosciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Inhibrx Biosciences, Inc. last report earnings?
Inhibrx Biosciences, Inc. (INBX) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0002007919-26-000028). This is Inhibrx Biosciences, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Inhibrx Biosciences, Inc.'s most recent earnings 8-K?
Inhibrx Biosciences, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0002007919-26-000028. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Inhibrx Biosciences, Inc.'s latest earnings 8-K →
Look up any company's CIK number →